Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21775336 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1KDM4E | |
| SCHEMBL21748713 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1KDM4E | |
| SCHEMBL21748714 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1KDM4E | |
| SCHEMBL5161271 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1KDM4E | |
| SCHEMBL21748986 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1TYK2 | |
| SCHEMBL21748984 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1TYK2 | |
| SCHEMBL21748987 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1TYK2 | |
| SCHEMBL30783197 | 0.86 | GPR119 (0.49) | GPR119USP30JAK2JAK1TYK2 | |
| SCHEMBL5226257 | 0.85 | TACR1 (0.47) | GPR119MEN1KMT2A | |
| SCHEMBL5159214 | 0.85 | TACR1 (0.47) | GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| CN-112236423-A | Piperidinyl-3- (aryloxy) propanamides and propionates | 武田药品工业株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | GPR119 31/4885USP30 1713/4885JAK2 1340/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | GPR119 31/4885USP30 1713/4885JAK2 1340/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | GPR119 31/4885USP30 1713/4885JAK2 1340/4885 |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | GPR119 31/4885USP30 1713/4885JAK2 1340/4885 |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | GPR119 31/4885USP30 1713/4885JAK2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.